Physician profile
Amir S Butt
NPI 1205931144
$4,243.63
in general payments reported to CMS, 2019-2025
9 companies · $1,390 in 2025
The $1,390 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,883 · 2023: $865 · 2024: $106 · 2025: $1,390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,228 · Food and Beverage: $1,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,228.05 |
| Food and Beverage | $1,132.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Uk Limited | $1,614.24 | 2022 | |
| Csl Behring | $1,374.62 | 2025 | |
| Boston Scientific Corporation | $280.64 | 2022-2023 | Spyglass |
| Olympus America INC. | $273.09 | 2023-2025 | Endoclot Phs, Disposable Grasping Forceps, Hanarostent Lowaxtm Duodenum/Pylorus(Nnn) |
| E.R. Squibb & Sons, L.L.C. | $227.74 | 2023-2024 | Zeposia |
| Conmed Corporation | $132.48 | 2023 | Conmed Biliary, Conmed Generators |
| Intercept Pharmaceuticals, INC. | $119.85 | 2022 | |
| Ferring Pharmaceuticals INC. | $113.22 | 2023 | Rebyota |
| Mallinckrodt Hospital Products INC. | $107.75 | 2023 | Terlivaz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amir Butt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.